Obesity India
- All
- News
- Videos
- Web Stories
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Is Bariatric Surgery Too Extreme? Surgeon Explains Why This Obesity Treatment Still Matters
Bariatric surgery is called extreme far more often than obesity itself is. That imbalance reflects how this condition is still viewed, by the public and, at times, even within medicine.
-
How A YouTuber Lost 10 Kg With Mounjaro And What It Did To His Emotions: 'Life Was Flat'
A YouTuber shared that while he lost 10 kg with Mounjaro, he also felt deprived of emotions. Irrespective of the situation, he remained neutral
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
No Smoking, No Alcohol, No Obesity: Doctor Explains Heart Disease Causes In Healthy Individuals
When patients present with heart disease despite a seemingly healthy lifestyle, it necessitates a deeper, personalised investigation.
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
Is Bariatric Surgery Too Extreme? Surgeon Explains Why This Obesity Treatment Still Matters
Bariatric surgery is called extreme far more often than obesity itself is. That imbalance reflects how this condition is still viewed, by the public and, at times, even within medicine.
-
How A YouTuber Lost 10 Kg With Mounjaro And What It Did To His Emotions: 'Life Was Flat'
A YouTuber shared that while he lost 10 kg with Mounjaro, he also felt deprived of emotions. Irrespective of the situation, he remained neutral
-
Semaglutide Patent Expires: Will Diabetes, Weight-Loss Treatment Become More Accessible For Patients?
Patent expiry does not signal a change in the medicine itself. Rather, it marks the beginning of wider competition, which typically leads to price reductions and improved availability.
-
Higher-Dose Wegovy Gets US Nod, Trials Show Over 20% Average Weight Loss, Says Drugmaker
Novo Nordisk said it plans to launch the new formulation, (semaglutide 7.2 mg), in the United States in April 2026.
-
Affordable Semaglutide Is Coming: Should You Be Worried About Drug Safety, Health Risks And Side Effects?
India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.
-
Ozempic's Key Molecule To Go Off-Patent: What Changes Now?
Patent protections on semaglutide, developed by Novo Nordisk, will lapse on March 20, opening the door for domestic pharmaceutical companies to manufacture and sell their own versions of the drug.
-
No Smoking, No Alcohol, No Obesity: Doctor Explains Heart Disease Causes In Healthy Individuals
When patients present with heart disease despite a seemingly healthy lifestyle, it necessitates a deeper, personalised investigation.
